Swiss National Bank lowered its position in shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by 1.5% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 621,741 shares of the biopharmaceutical company’s stock after selling 9,600 shares during the period. Swiss National Bank owned 0.28% of Alexion Pharmaceuticals worth $76,188,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ALXN. Global X Management Co. LLC boosted its position in shares of Alexion Pharmaceuticals by 1,416.4% in the third quarter. Global X Management Co. LLC now owns 925 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 864 shares in the last quarter. Cornerstone Advisors Inc. boosted its position in shares of Alexion Pharmaceuticals by 47.4% in the third quarter. Cornerstone Advisors Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 310 shares in the last quarter. NEXT Financial Group Inc boosted its position in shares of Alexion Pharmaceuticals by 66.1% in the second quarter. NEXT Financial Group Inc now owns 1,106 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 440 shares in the last quarter. Bellwether Investment Group LLC purchased a new position in shares of Alexion Pharmaceuticals during the second quarter worth $172,000. Finally, Charlemagne Capital Ltd. purchased a new position in shares of Alexion Pharmaceuticals during the second quarter worth $191,000. 94.85% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) opened at 119.38 on Tuesday. Alexion Pharmaceuticals Inc. has a one year low of $110.56 and a one year high of $193.45. The stock’s 50 day moving average price is $122.56 and its 200 day moving average price is $128.72. The firm has a market capitalization of $26.76 billion, a PE ratio of 72.79 and a beta of 1.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.04 by $0.19. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The business earned $799 million during the quarter, compared to analysts’ expectations of $787.07 million. During the same period in the prior year, the company earned $1.16 earnings per share. The business’s revenue was up 19.9% compared to the same quarter last year. Analysts expect that Alexion Pharmaceuticals Inc. will post $4.64 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Swiss National Bank Cuts Position in Alexion Pharmaceuticals Inc. (ALXN)” was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. and international copyright law. The correct version of this news story can be read at https://www.thecerbatgem.com/2016/11/29/swiss-national-bank-cuts-position-in-alexion-pharmaceuticals-inc-alxn.html.

Several research firms recently issued reports on ALXN. Barclays PLC upgraded Alexion Pharmaceuticals from an “equal weight” rating to an “overweight” rating in a research report on Tuesday. Piper Jaffray Cos. set a $176.00 price objective on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, November 6th. Vetr lowered Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $150.62 price objective on the stock. in a research report on Wednesday, August 3rd. Zacks Investment Research lowered Alexion Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 2nd. Finally, Deutsche Bank AG started coverage on Alexion Pharmaceuticals in a research report on Thursday, November 3rd. They issued a “buy” rating and a $164.00 price objective on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $173.36.

In related news, Director Leonard Bell sold 37,317 shares of the stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $140.38, for a total transaction of $5,238,560.46. Following the completion of the transaction, the director now directly owns 440,936 shares of the company’s stock, valued at $61,898,595.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Julie O’neill sold 650 shares of the stock in a transaction dated Friday, September 2nd. The stock was sold at an average price of $126.29, for a total transaction of $82,088.50. Following the transaction, the executive vice president now directly owns 35,384 shares of the company’s stock, valued at $4,468,645.36. The disclosure for this sale can be found here. Corporate insiders own 4.41% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.